AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2240505 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine 1.0 mg/kg, droperidol 0.15 mg/kg, methadone 0.08 mg/kg
Number of subjects: 100
Study 319938 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (2, 6‐dichlorobenzylidene aminoguanidine acetate) 4 to 16 mg twice daily
Number of subjects: 55
Study 319938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounding (Earthing) during work and sleep for four weeks
Number of subjects: 16
Study 30448083 — intervention group
Group type: COMPARATOR
Intervention: Not grounded (control group) for the first week and last week
Number of subjects: 16
Study 30448083 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounding (Earthing) at one month follow-up
Number of subjects: 16
Study 29242250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2 intravenously on days 1, 4, 8, and 11, n=21)
Number of subjects: 44
Study 29242250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 44
Study 29242250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 44
Study 26854669 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0
Study 26854669 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 26854669 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin combined with metformin
Number of subjects: 0
Study 26854669 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 0
Study 23968339 — intervention group
Group type: EXPERIMENTAL
Intervention: D. farinae drops plus pharmacotherapy (treatment group)
Number of subjects: 107
Study 23968339 — intervention group
Group type: COMPARATOR
Intervention: Only pharmacotherapy (control group)
Number of subjects: 107
Study 22331267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling (specifically the overexpression of SNORD genes: SNORD25, SNORD27, SNORD30, and SNORD31)
Number of subjects: 0
Study 22331267 — intervention group
Group type: COMPARATOR
Intervention: Chromosomal abnormalities detected by FISH and SNP‐arrays
Number of subjects: 0
Study 20937743 — intervention group
Group type: EXPERIMENTAL
Intervention: FVL/PT mutation carriers
Number of subjects: 363
Study 20937743 — intervention group
Group type: COMPARATOR
Intervention: FVL/PT non-carriers
Number of subjects: 363
Study 20937743 — intervention group
Group type: EXPERIMENTAL
Intervention: FVL/PT mutations
Number of subjects: 363
Study 17557339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological therapy
Number of subjects: 17
Study 17557339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 17
Study 17557339 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 17
Study 15809950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of 350 mm Hg
Number of subjects: 57
Study 15809950 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet pressure of systolic blood pressure (SBP) plus 100 mm Hg
Number of subjects: 57
Study 11518845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4-6 mg/daily)
Number of subjects: 20
Study 11518845 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg/daily)
Number of subjects: 20
Study 10205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabbage leaf extract cream
Number of subjects: 39
Study 10205435 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 39
Study 10205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding (not a cream intervention)
Number of subjects: 39
Study 8172501 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, intensive, supervised rehabilitation program (9 treatments combined with home exercises)
Number of subjects: 31
Study 8172501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific physiotherapy treatment, only instructions and prescribed exercises)
Number of subjects: 31
Study 2974259 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural dexamethasone (4 mg)
Number of subjects: 39
Study 2974259 — intervention group
Group type: COMPARATOR
Intervention: No steroid (group T)
Number of subjects: 39
Study 31056239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal (AC) catheter
Number of subjects: 151
Study 31056239 — intervention group
Group type: COMPARATOR
Intervention: Femoral triangle (FT) catheter
Number of subjects: 151
Study 29115200 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high‐molecular weight (HMW) barley β‐glucan
Number of subjects: 30
Study 25512446 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12
Study 25512446 — intervention group
Group type: COMPARATOR
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 12
Study 24289597 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 100
Study 24289597 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message by phone (SMS)
Number of subjects: 100
Study 24289597 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered letter
Number of subjects: 100
Study 24289597 — intervention group
Group type: COMPARATOR
Intervention: Postal letter
Number of subjects: 100
Study 21466903 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (HB); 40 min/session, at least three times per week, combined with slight caloric restriction of 100-300 calories per day.
Number of subjects: 185
Study 21466903 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG); slight caloric restriction of 100-300 calories per day.
Number of subjects: 185
Study 18649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 30
Study 18649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinse
Number of subjects: 30
Study 18649561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical fluoride agents)
Number of subjects: 30
Study 16866587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of a preselected negative memory during a stream‐of‐consciousness (SOC) task
Number of subjects: 0
Study 16866587 — intervention group
Group type: COMPARATOR
Intervention: No suppression condition (control)
Number of subjects: 0
Study 16866587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of memories
Number of subjects: 0
Study 16866587 — intervention group
Group type: COMPARATOR
Intervention: Participants not asked to suppress memories
Number of subjects: 0
Study 12670382 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 98
Study 12670382 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 98
Study 12670382 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 10833093 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (600 mg/day) in addition to alpha‐IFN (3 MU three times weekly)
Number of subjects: 103
Study 9234209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure rotation in place (180 deg)
Number of subjects: 12
Study 9234209 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear motion (4.5 m)
Number of subjects: 12
Study 9234209 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicircular trajectory (radius, 1.5 m; angular acceleration, 0.2 rad s‐2)
Number of subjects: 12
Study 9234209 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movements
Number of subjects: 12
Study 7535512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin (0.1%)
Number of subjects: 10
Study 7535512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2455154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20-80 mg, median 40 mg)
Number of subjects: 45
Study 2455154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (40-80 mg, median 60 mg)
Number of subjects: 45
Study 2455154 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 45
Study 2455154 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 45
Study 30197501 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg once a day for 1 month, then 100 mg once a day for 12 months
Number of subjects: 182
Study 30197501 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once a day for 1 month, then 25 mg once a day for 12 months
Number of subjects: 182
Study 26747458 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (500 mg, five/day)
Number of subjects: 96
Study 26747458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24480637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg pilsicainide hydrochloride
Number of subjects: 30
Study 24480637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg pilsicainide hydrochloride
Number of subjects: 30
Study 24480637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg pilsicainide hydrochloride
Number of subjects: 30
Study 24059346 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person, group-based intervention (9 modules delivered over 10 sessions)
Number of subjects: 660
Study 24059346 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (13 modules)
Number of subjects: 660
Study 24059346 — intervention group
Group type: COMPARATOR
Intervention: Control group (mailed literature)
Number of subjects: 660
Study 24059346 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person, group-based intervention
Number of subjects: 660
Study 24059346 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 660
Study 24059346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 20800632 — intervention group
Group type: EXPERIMENTAL
Intervention: ND-CCK (Normal Diet with CCK-8 infusion)
Number of subjects: 14
Study 20800632 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD-CCK (High-Fat Diet with CCK-8 infusion)
Number of subjects: 14
Study 20800632 — intervention group
Group type: COMPARATOR
Intervention: ND-SAL (Normal Diet with saline infusion)
Number of subjects: 14
Study 18719452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed mode radiofrequency
Number of subjects: 5
Study 18719452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mode radiofrequency
Number of subjects: 5
Study 18719452 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 5
Study 16628152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture point (AcP) at Stomach‐36
Number of subjects: 20
Study 16628152 — intervention group
Group type: COMPARATOR
Intervention: Non-AcP region (control)
Number of subjects: 20
Study 11790641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (exact dosage and duration not specified)
Number of subjects: 59
Study 11790641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9579256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 9579256 — intervention group
Group type: COMPARATOR
Intervention: Face Mask (FM)
Number of subjects: 60
Study 7714375 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved group
Number of subjects: 28
Study 7714375 — intervention group
Group type: COMPARATOR
Intervention: Non-preserved group
Number of subjects: 28
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (immediate removal after bladder was emptied)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (removal 24 hours later)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (removal 48 hours later)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (overall)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (successful patients reviewed 6 months later)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (overall conclusion)
Number of subjects: 60
Study 2641206 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial without catheter (recommendation)
Number of subjects: 60
Study 410296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 130
Study 410296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiation therapy with hydroxyurea
Number of subjects: 130
Study 7010976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation
Number of subjects: 30
Study 7010976 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study 31784442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (P6 acupuncture)
Number of subjects: 180
Study 31784442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal thumbtack needle group (P6 intradermal needle)
Number of subjects: 180
Study 31784442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 31784442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 180
Study 31784442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal thumbtack needle group
Number of subjects: 180
Study 31784442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 29802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET) for 8 weeks
Number of subjects: 30
Study 29802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 8 weeks
Number of subjects: 30
Study 29802649 — intervention group
Group type: COMPARATOR
Intervention: Healthy age‐matched subjects (Control)
Number of subjects: 30
Study 26875887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction + OA debridement and functional rehabilitation training under arthroscopy
Number of subjects: 68
Study 26875887 — intervention group
Group type: COMPARATOR
Intervention: Analgesic, anti-inflammatory drugs + functional rehabilitation training
Number of subjects: 68
Study 24585701 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI + DIET + EX
Number of subjects: 48
Study 24585701 — intervention group
Group type: COMPARATOR
Intervention: DIET + EX
Number of subjects: 48
Study 22074188 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (2 mg/ml) + heparin (2000 U/ml)
Number of subjects: 131
Study 22074188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (5 mg/ml) + heparin (2000 U/ml)
Number of subjects: 131
Study 22074188 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (2000 U/ml) alone
Number of subjects: 131
Study 19349549 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T-H (doxorubicin, cyclophosphamide, weekly paclitaxel, and trastuzumab)
Number of subjects: 1503
Study 19349549 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-TH-H (doxorubicin, cyclophosphamide, weekly paclitaxel, and trastuzumab)
Number of subjects: 1503
Study 19349549 — intervention group
Group type: COMPARATOR
Intervention: AC-T (doxorubicin, cyclophosphamide, and weekly paclitaxel)
Number of subjects: 1503
Study 17932235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 101
Study 17932235 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 101
Study 15356676 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP), 40 mg/day, oral medication for 2 weeks
Number of subjects: 15
Study 15356676 — intervention group
Group type: COMPARATOR
Intervention: Placebo, oral medication for 2 weeks
Number of subjects: 15
Study 11994699 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with birch pollen extract
Number of subjects: 49
Study 11994699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9667298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 9667298 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30
Study 7842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting fluid A (4% or 5%)
Number of subjects: 10
Study 7842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting fluid B (4% or 5%)
Number of subjects: 10
Study 7842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting fluid C (4% or 5%)
Number of subjects: 10
Study 7842676 — intervention group
Group type: COMPARATOR
Intervention: Control (water probe)
Number of subjects: 10
Study 2530019 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (37 pmol min-1 kg-1)
Number of subjects: 8
Study 2530019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 765873 — intervention group
Group type: EXPERIMENTAL
Intervention: High intravenous doses of methylprednisolone (1 g intravenously on alternate days, maximum of four injections)
Number of subjects: 48
Study 765873 — intervention group
Group type: COMPARATOR
Intervention: Increased daily prednisolone doses (300 mg first day, 200 mg second day, 100 mg third day, tapering down over weeks)
Number of subjects: 48
Study 765873 — intervention group
Group type: EXPERIMENTAL
Intervention: High intravenous doses of methylprednisolone
Number of subjects: 48
Study 31325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral Follicle Count (AFC) based gonadotropin dosing
Number of subjects: 200
Study 31325336 — intervention group
Group type: COMPARATOR
Intervention: Serum Anti-Müllerian Hormone (AMH) based gonadotropin dosing
Number of subjects: 200
Study 31325336 — intervention group
Group type: EXPERIMENTAL
Intervention: AFC based gonadotropin dosing
Number of subjects: 200
Study 31325336 — intervention group
Group type: COMPARATOR
Intervention: AMH based gonadotropin dosing
Number of subjects: 200
Study 31325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of AFC > 5
Number of subjects: 200
Study 31325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of AFC ≤ 5
Number of subjects: 200
Study 31325336 — intervention group
Group type: EXPERIMENTAL
Intervention: AFC and AMH categorization
Number of subjects: 200
Study 30907130 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimedia-based nursing visit
Number of subjects: 128
Study 30907130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multimedia-based nursing visit)
Number of subjects: 128
Study 27503364 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular grapefruit juice (RGJ)
Number of subjects: 12
Study 27503364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-furanocoumarin hybrid grapefruit juice (HGJ)
Number of subjects: 12
Study 27503364 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 25162304 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention with four home visits over four months.
Number of subjects: 101
Study 25162304 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm receiving four newsletters covering the same topics.
Number of subjects: 101
Study 23820927 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 34
Study 23820927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21614811 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV detection and genotyping using PCR‐SPF10/LiPA (INNOLiPA Extra Amp)
Number of subjects: 67
Study 21614811 — intervention group
Group type: EXPERIMENTAL
Intervention: p16INK4a immunodetection using antibody clone E6H4
Number of subjects: 67
Study 19627683 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape of exercises and instructions to support routine physiotherapy consultations
Number of subjects: 33
Study 19627683 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape of exercises and instructions
Number of subjects: 33
Study 19627683 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape of exercises
Number of subjects: 33
Study 16886585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal before exercise
Number of subjects: 12
Study 16886585 — intervention group
Group type: COMPARATOR
Intervention: Placebo before exercise
Number of subjects: 12
Study 15579798 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Number of subjects: 22
Study 15579798 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Number of subjects: 22
Study 11603848 — intervention group
Group type: EXPERIMENTAL
Intervention: freeze-dried U guianensis
Number of subjects: 45
Study 11603848 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 9821760 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention by primary care physicians with feedback and monitoring of symptoms and clinical findings including biochemical markers; self-help pamphlet recommended.
Number of subjects: 0
Study 9821760 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum gamma‐glutamyl transpeptidase (GGT) level as a biochemical marker.
Number of subjects: 0
Study 9821760 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-judgmental lifestyle approach to define problems in terms of lifestyle habits and consequences.
Number of subjects: 0
Study 8123837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 monoclonal antibody (MoAb) treatment
Number of subjects: 0
Study 8123837 — intervention group
Group type: COMPARATOR
Intervention: Low proliferative index
Number of subjects: 0
Study 8123837 — intervention group
Group type: COMPARATOR
Intervention: High proliferative index
Number of subjects: 0
Study 2523661 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.6 microgram/kg/minute, decreasing to 0.3 microgram/kg/minute)
Number of subjects: 20
Study 2523661 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (1 microgram/kg/minute)
Number of subjects: 20
Study 331835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg three times a day)
Number of subjects: 30
Study 331835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30